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INTRODUCTION
Postpartum urinary retention (PUR) is an obstetric
case that is often encountered in clinical practice.
The reported PUR prevalence varies from 1.7 to
17.9% focusing on PUR after vaginal delivery.
Groutz et al. studied 125 women with postpartum
voiding difficulties, as many as 38% of maternal
women with the aid of vacuum instrumentation,
27% with spontaneous labour, and 15% with
cesarean section.1,2
According to Weissman, factors including episio-
tomy, birth trauma, and severe perineal lacerations
are not sufficient enough to induce PUR. On the
contrary, there is some evidence to indicate the
strong correlation between cesarean section and
Abstract
Objective: To determine the effect of misoprostol on the
incidence of urinary retention in post-cesarean section
patients by measuring maternal residual urine volume 6 hours
after catheter removal.
Methods: This was a single-blind randomized controlled trial,
at Department of Obstetrics and Gynecology Dr. Mohammad
Hoesin Palembang Hospital from October 2016 to February
2017. Samples were patients who underwent cesarean section,
either elective or emergencies treated at Department of
Obstetrics and Gynecology Hospital, Dr. Mohammad Hoesin
Palembang. Subjects were allocated into two groups: treatment
group (receiving misoprostol) and placebo group. Urinary
retention is diagnosed if post-voiding residual urine volume
after Foley catheter removal was >200 ml. Statistical analysis
was performed using SPSS 17.0
Results: There were no differences in mean time between of
urination between control group (placebo) and 600g oral
misoprostol group. The average of urine volume and residual
urine volume between control group (placebo) and 600g oral
misoprostol group was significantly different. 600g miso-
prostol orally can increase the amount of urine and reduce the
volume of urinary residue after cesarean section.
Conclusion: 600g oral misoprostol can increase urine volume
and reduce volume of residual urine post-cesarean section.
[Indones J Obstet Gynecol 2018; 6-4: 248-252]
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Abstrak
Tujuan: Untuk mengetahui pengaruh misoprostol terhadap kejadian
retensi urin pada pasien operasi seksio sesarea dengan mengukur vo-lume residu urin maternal 6 jam setelah kateter dilepaskan.
Metode: Penelitian uji klinik acak berpembanding (RandomizedControlled Trial) secara single blind (tersamar tunggal) ini di-
lakukan di Departemen Obstetri dan Ginekologi RSUP Dr.
Mohammad Hoesin Palembang mulai bulan Oktober 2016 sampaidengan Februari 2017. Sampel penelitian adalah semua pasien
seksio sesarea, baik elektif maupun emergensi yang dirawat diDepartemen Obstetri dan Ginekologi RSUP Dr. Mohammad Hoesin
Palembang. Subjek dialokasikan menjadi 2 kelompok yaitu ke-
lompok penanganan yang menerima misoprostol dan kelompokplasebo. Retensio urin didiagnosis jika volume residu urin pas-
caberkemih setelah kateter Foley dilepaskan >200 ml. Analisis
statistik dilakukan dengan menggunakan SPSS 17.0
Hasil: Tidak terdapat perbedaan rerata waktu urinasi antara kelom-
pok kontrol (plasebo) dengan misoprostol peroral 600g.Terdapat
perbedaan rerata jumlah urin, dan volume residu urin antara
kelompok kontrol (plasebo) dengan misoprostol peroral 600g.
Misoprostol per oral 600g dapat meningkatkan jumlah urin
dan mengurangi volume residu urin pascapersalinan seksio se-
sarea.
Kesimpulan: Misoprostol per oral 600g dapat meningkatkan jum-lah urin dan mengurangi volume residu urin pascapersalinan
seksio sesarea
[Maj Obstet Ginekol Indones 2018; 6-4: 248-252]
Kata kunci: misoprostol, retensio urin, seksio sesarea
Correspondence: Febrinata Mahadika. embi010282@gmail.com
Indones J
248  Mahadika et al Obstet Gynecol
PUR incidence. Kermans et al. stated the preva-
lence of post-cesarean section PUR is higher than
vaginal delivery (2.1% vs 3.2%). Intraoperative
bladder manipulation is thought to be the cause of
weak detrusor muscle contractions. Patients
terminated abdominally tend to be unable to
empty the bladder due to inadequate contraction
of detrusor muscles postoperative; patients are
also reluctant to contract the abdominal wall to
start urinary expenditure. Epidural anaesthesia
may also decrease or exclude sensations of urgency
from the need for urination during labour and the
postpartum period.3-7
Inaccuracies or delays in diagnosis and manage-
ment of PUR can cause excessive distension of the
bladder, detrusor muscle damage, and increase risk
of urinary tract infections, long-term voiding dys-
function and renal injury.3
Prostaglandin (PGS) is essential to improve
detrusor muscle contraction. Misoprostol is an
analogue of prostaglandin E1 (PGE1) synthetic. It
has various advantages, including relatively afford-
able price, widely available, has long half-life, and
stable at room temperature. Kelly et al. reported
that within three months of therapy using oral PGS
analogue 600 mg per day, 56% of patients reported
improvement of interstitial cystitis symptoms,
especially voiding disturbance due to pain and
urine retention.8-10
Until today, effectiveness of misoprostol in
preventing and overcoming urinary retention after
cesarean section at Dr Mohammad Hoesin
Palembang has not been studied. Therefore, this
study aimed to determine the effect of misoprostol
on the incidence of urinary retention in patients
with cesarean section by measuring maternal re-
sidual urine volume 6 hours after catheter removal.
METHODS
This single-blind randomised controlled trial was
conducted at the Department of Obstetrics and
Gynecology Dr. Mohammad Hoesin Palembang
Hospital in October 2016 until February 2017.
Samples were all patients underwent elective
and emergency cesarean sections, treated in
Department of Obstetrics and Gynecology, Dr.
Mohammad Hoesin Palembang Hospital. Inclusion
criteria were patients undergoing cesarean sec-
tions at Dr. Mohammad Hoesin Palembang
hospital by lower uterine segment incision, with
regional anaesthesia, and those willing to partici-
pate in this research and signed informed consent.
On the contrary, patients with urinary tract infec-
tions, having previous voiding problems prior to
caesarean section, patients with severe preeclamp-
sia, diabetes mellitus, renal dysfunction, and indi-
cations of cesarean section; those with prolonged
labor, history of cesarean section, polyhydramnios,
multiple pregnancies, and induction of labor with
misoprostol were excluded from the study. Patient
who has a habit or a history of smoking and alcohol
consumption were also excluded from the study.
Patients were dropped out from the analysis if
experiencing allergic or hypersensitivity during
administration of misoprostol and suffered from
urosepsis. Based on samples calculation, 15
samples were needed in each group. Sample was
chosen by simple random sampling.
All post-cesarean patients who were treated at
Department of Obstetrics and Gynecology Dr.
Mohammad Hoesin Palembang Hospital and met
the inclusion criteria were asked to sign the in-
formed consent, subjects then being matched
based on age, parity, and gestational age. Simple
random sampling was applicated to allocate
subjects who received misoprostol and placebo.
Sample did not know in which treatment group the
belonged to.
Treatment group received 600 mcg misoprostol
per day, administered orally after the patient com-
pleted a cesarean section. It was divided into three
doses; 200 mcg orally after cesarean section, 200
mcg orally within 8 hours after the first dose, 200
mcg in 8 hours after administration of the second
dose. Control group received a placebo in the form
of three tablets of starch material. Placebo tablet
was administered the same way as misoprostol.
Foley catheter installed for 24 hours in post-
cesarean section patients. After 24 hours post-
surgery, catheter was removed, and patient was
asked to urinate. Time interval between urination
and time of catheter removal was then recorded.
Patient was asked to collect urine in a bottles and
researcher would measure the amount of urine
volume in the bottle using a measuring cup. After
the first voiding (after Foley catheter was re-
moved), residual urine volume was measured by
catheter. Catheterization was done using 16F
Foley catheter as soon as voiding. Urine residues
was collected in urine bag to measure urine vo-
lume. If the residual urine volume was >200 ml,
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patient could be diagnosed with urinary retention
after cesarean section. If the patient was not able
to urinate spontaneously 6 hours after Foley
catheter was removed, patient could be diagnosed
with urinary retention after cesarean section.
Patients underwent catheterisation and urine
volume was measured.
Data was collected using forms previously
provided, and then it was analysed using X2 test
for dichotomous variables and t tests for con-
tinuous variables. To determine the significance
of differences between residual urine volume
between misoprostol group and placebo group,
data tes normality was performed with Shapiro
Wilk test. If data were normally distributed,
the unpaired t-test would be used. If data were
not normally distributed, non-parametric Mann-
Whitney test would be used. Differences were
considered significant if p <0.05. All data were
analysed using SPSS version 18.
RESULTS
Population of this study were 30 pregnant women
who underwent cesarean section and met inclusion
and exclusion criteria. 15 women were located in
the treatment group and 15 women as control in
the placebo group. After follow-up, no research
subject was dropped out or withdrawal from this
study. Mean of urination time between control and
treatment group was not significantly different (p
= 0.589) (Table 1).
Table1. Comparison of Oral Misoprostol 600 g and
Placebo Group Based on Urination time
Variable 600 g Oral
Misoprostol
Placebo p*
Time (Hour) 2.467  0.972 2.667  1.029 0.589*
*Independent T test, p = 0.05
Mean urine volume between control group
(placebo) and treatment group was significantly
different (p = 0.029) (Table 2). Mean of urine
volume was higher in treatment group.
Table 2. Comparison of 600 g Oral Misoprostol and
Placebo Group Based on Urine Volume
Variable 600 g Oral
Misoprostol
Placebo p*
Urinary
Volume (cc) 425.33  71.20 320.00  157.21 0.029*
*Independent T-test, p = 0.05
Mean of residual urine volume between control
group (placebo) and treatment group was signifi-
cantly different (p = 0.001) (Table 3). Mean of re-
sidual urine volume was lower in treatment group.
Table 3. Comparison of 600 g Oral Misoprostol and Pla-
cebo Group Based on Residual Urine Volume
Variable 600 g Oral
Misoprostol
Placebo p*
Urinary Volume
Residue (cc) 112.67  28.59 147.33  24.33 0.001*
*Independent T-test, p = 0.05
DISCUSSION
Urinary retention after cesarean section is the
inability to urinate 6 hours after Foley catheter
removal or the volume of residual urine is > 200
ml. There are two parameters to diagnose urinary
retention in this study including urination time,
interpreting the time interval since Foley catheter
removal until the patient can void spontaneously
and residual volume, which is the amount of
residual urine post spontaneous urination, as
measured by catheterisation methods.
Before treatment, the characteristics of research
subjects were statistically researched, the results
of which, age (p = 0.407), body mass index (p =
0.489), and parity (p = 0.244) between the two
groups did not differ significantly. It confirms that
the differential effectiveness of 600g oral miso-
prostol with placebo in preventing the occurrence
of postpartum urinary retention is not influenced
by demographic characteristics.
This study also showed there are no differences
between the mean time urination between the con-
trol group (placebo) and misoprostol orally 600 g
(p = 0.589), in which both the misoprostol group
and placebo, all pregnant women after cesarean
section were able to urinate 6 hours after the
catheter Foley released. The results of this study
differs from the research conducted by Azami and
Gatut in 2013 which showed differences between
the mean time urination between the control group
(placebo) with 600g oral misoprostol (p = 0.010).
PGS role in relaxation-contraction and sensitivity
to stimuli urinary bladder has been widely studied,
PGS released during or immediately after the
occurrence of bladder distention, and PGS also
regulates smooth muscle contraction and modu-
lates neuronal transmission in urinary tract.11,12
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Therefore, it can be concluded that misoprostol
can increase sensitivity to stimuli urinary bladder,
that is distended bladder with urine, and accele-
rates urination time in the study samples.
The was no difference of urination time in both
study groups (misoprostol vs placebo), this might
be caused by several factors, such as, the whole
research samples were from pregnancies with no
disorders that affect micturition (examples: UTI,
cystitis, neurological disorders, prolonged labor,
renal dysfunction, preeclampsia, smoking, alcohol,
etc.) so that the samples were all under normal
urination condition.
Intraoperative bladder manipulation occurred
minimally. It was mentioned earlier that one of the
exclusion criteria for the study was pregnancies
with complication, so the cesarean section opera-
tion may take place smoothly without any difficulty
that may involve manipulation of bladder.
Fluid intake in this study could not be controlled
by the researcher. It is known that fluid intake
pre-operative or post-operative determines urine
production which then would affect the urination
time. However, the calculation of urine time of all
samples were after catheter removal, which means
all samples at the beginning of the calculation of
urination time had an empty bladder.
Both groups were installed foley catheters until
24 hours post-operative. A study conducted by T
Mohammad Rizki in 2009 showed a significant
association between the length of catheter inser-
tion with urinary retention, where the faster the
settled catheter was removed, the incidence of
urinary retention was increased by p = 0.038
(p <0.05).
A small amount of samples. A study with 30
samples, with each group of 15 samples, may be
less representative of the population, so no time
difference in urination was found. This is one of
the weaknesses of the study, so it is expected that
in the next study should involve a larger sample
size.
Prevention of urinary retention in obstetric
cases can be done in several ways, among others,
by overcoming postpartum pain, by installing a
Foley catheter for 24 hours or by administration
of PGS. The release of PGS by the bladder can be
stimulated by a variety of factors, including
neuropeptides (substance P, neurokinin A), and
inflammatory factor (bradykinin), which causes
vesicular contractions and facilitates urinary
reflex.4
In this study statistical analysis showed that
there was a difference in the mean number of urine
volume between the control group (placebo) with
600 g oral misoprostol, in which the urine volume
of group who received 600 g peroral misoprostol
was more than the group who received placebo.
The results of this study were slightly different
from the Azami and Gatut research in 2013 where
the results showed no difference in the mean
volume of urine between the control group
(placebo) with 600 g per oral misoprostol (p =
0.051). However, the same result was found the
amount of urine volume in the misoprostol group
was higher than those of the placebo group. This
difference is probably due to the research of Azami
and Gatut route of misoprostol was suppository.
After oral administration, the half-life of miso-
prostol ranges from 20 to 40 minutes, then de-
creases rapidly within 120 minutes and remains
low whereas at rectal administration is less than
20 minutes.8,12
Another possible cause is the uncontrollable
fluid intake in this study as discussed earlier. After
oral administration, misoprostol is faster and
almost entirely absorbed by the gastrointestinal
tract, plasma peak levels are achieved in 30
minutes, while the half-life ranges from 20-40
minutes, then decreases rapidly within 120
minutes and remains low. Misoprostol plays a role
in opening Ca2 + ion channels so that extracellular
Ca2 + ions can enter easily into intracellular and
bind to calmodulin. This bond further activates
the formation of MLC kinase which facilitates the
formation of P-myosin. P-myosin will bind to actin
causing contraction of detrusor muscle. Detrusor
muscle contractions will trigger the function of the
bladder to return to normal.9
In addition to urinary and urine volume time,
another parameter for assessing postpartum
urinary retention is the volume of urine residue
> 200 ml. With statistical analysis, this study
showed that there was a difference in mean
residual urine volume between the control
group (placebo) and 600 g oral misoprostol, in
which the volume of urine residues of the group
receiving peripheral misoprostol was 600 g
less than those receiving placebo, but no residual
volume was found > 200 ml in both misoprostol
and placebo groups.
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The results of this study were not much different
from the research done by Azami and Gatut in
2013 where the results showed that there was a
difference of average urine volume between the
control group (placebo) and 600 g (p <0.001) oral
misoprostol, whereas the volume of urine residues
of the group receiving 600 g oral misoprostol less
than those receiving placebo and no residual
volume > 200 ml was found in either the miso-
prostol or placebo group.12
So it can be concluded that in this study 600g
oral misoprostol can increase the amount of urine
volume and reduce the volume of residual urine
after cesarean section.
The majority side effect of misoprostol in this
study (20% of 15 samples) was shivering. These
findings are consistent with the study of Azami
and Gatut (2003) who found 38% of shivering
incidents. Other adverse effects were diarrhoea,
Wagner (1985) has documented adverse drug
events of oral route misoprostol in the gastro-
intestinal tract and suggested that rectal route
delivery is safer to prevent the adverse effects of
misoprostol in the gastrointestinal tract. Other
possible causes of diarrhoea in this study include
electrolyte imbalances, gastroenteritis-associated
diseases that may be suffered by the patient and
undetected during the study.
The results of the fisher exacts analysis found
no significant association between the types of
intervention and the incidence of drug side effects,
suggesting that the adverse effects of drugs on the
study could be "brutal" and not necessarily caused
by misoprostol. The patient’s subjectivity bias for
shivering perception can disrupt the analysis of
drug side effects, and this bias is difficult to control.
A larger sample size is needed to determine if side
effects do occur, and what are the side effects that
may result from misoprostol administration.
Some disadvantages in this study besides the
small number of samples is not to include patients
with PUR (+). All samples did not experience
PUR, and the effectiveness analysis of misoprostol
was done on non PUR samples. Secondly, no miso-
prostol was administered in different doses, so this
study could not determine the best dose of miso-
prostol for PUR handling, as well as the possible
toxic effects based on misoprostol dosage. Further
research is expected to include post-cesarean
serum PUR population with larger sample
quantities and provide varying doses of miso-
prostol intervention.
CONCLUSION
There is no difference in mean time of urination
between the control group (placebo) with 600g
oral misoprostol. There is an average difference in
the amount of urine volume, and the volume of re-
sidual urine between the control group (placebo)
with 600g oral misoprostol. 600g oral miso-
prostol can increase the amount of urine and re-
duce the volume of urinary residue after cesarean
section.
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